{
}
Recipharm is expanding its Monts production center in France to manufacture the Moderna vaccine, creating 100 jobs, despite challenges in recruiting skilled talent. The decision to relocate production is driven by economic interests, environmental concerns, and a desire to strengthen national sovereignty in the face of global supply chain vulnerabilities highlighted by the Covid-19 pandemic. The SYMBIOSE project represents a significant investment in the future of French industry, aiming to balance relocation with securing critical supplies from various regions.
Recipharm Monts SAS
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
recipharm expands production in france amid shifting global supply chains
12:12 15.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Global Trade Developments
Stock Market Updates
Cryptocurrency Trends
Startups & Entrepreneurship
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Supply Chain Management
Central Banks and Digital Currencies
CEO Changes
Workplace Trends
Blockchain Infrastructure Development
Crypto Policies and Governance
Banking Regulations
Central Bank Actions
Finance Mergers & Acquisitions
Venture Capital Investments
Retail and Consumer Goods
Market Analysis and Predictions
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Tesla, Inc.
MARA Holdings, Inc.
Cleanspark Inc
Citigroup Inc.
Vodafone Idea Limited
JM Financial Limited
Fuse Science, Inc.
Arla Foods A.M.B.A.
Currencies:
People: